Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

ABSTRACT: Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment

PROVIDER: PRJNA384841 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Next Generation Sequencing to Identify Targets of the C. albicans Dfi1 Pathway

Project description:Next Generation Sequencing to Identify Targets of the C. albicans Dfi1 Pathway

| PRJNA797036 | ENA

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas.

Project description:Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas from 10 centres were studied. Median age was 11.5 years (range 1-18). Twenty-two (31%) had at least one pathogenic alteration by NGS. Thirty pathogenic mutations in 18 different genes were detected amongst the 22 patients. The most frequent alterations were found in TP53, followed by FGFR4 and CTNNB1. Combining all biological studies, 18 actionable variants were detected and six patients received targeted treatment observing a disease control rate of 78%. Extrapolating the results to the whole cohort, 23% of the patients would obtain clinical benefit from this approach. Conclusions: Paediatric sarcomas have a different genomic landscape when compared to adult cohorts. Incorporating NGS targets into paediatric sarcomas' therapy is feasible and allows personalized treatments with clinical benefit in the relapse setting.

| S-EPMC8067272 | biostudies-literature

Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Project description:We determined the frequency of recurrent hotspot mutations in 46 cancer-related genes across tumor histologies in patients with advanced cancer.We reviewed data from 500 consecutive patients who underwent genomic profiling on an IRB-approved prospective clinical protocol in the Phase I program at the MD Anderson Cancer Center. Archival tumor DNA was tested for 740 hotspot mutations in 46 genes (Ampli-Seq Cancer Panel; Life Technologies, CA).Of the 500 patients, 362 had at least one reported mutation/variant. The most common likely somatic mutations were within TP53 (36%), KRAS (11%), and PIK3CA (9%) genes. Sarcoma (20%) and kidney (30%) had the lowest proportion of likely somatic mutations detected, while pancreas (100%), colorectal (89%), melanoma (86%), and endometrial (75%) had the highest. There was high concordance in 62 patients with paired primary tumors and metastases analyzed. 151 (30%) patients had alterations in potentially actionable genes. 37 tumor types were enrolled; both rare actionable mutations in common tumor types and actionable mutations in rare tumor types were identified.Multiplex testing in the CLIA environment facilitates genomic characterization across multiple tumor lineages and identification of novel opportunities for genotype-driven trials.

| S-EPMC4652990 | biostudies-literature

On/Off targets INDEL analysis by Next Generation Sequencing

Project description:On/Off targets INDEL analysis by Next Generation Sequencing

| PRJNA746584 | ENA

Next Generation Sequencing to Identify Targets of the C. albicans Dfi1 Pathway

Project description:Purpose: To identify downstream genetics targets of the Dfi1 pathway during Dfi1 activating conditions. Methods: WT and dfi1 null cells were grown in minimal media, then treated with either 4uM of the calcium ionophore A23187 or an equal volume of 100% ethanol vehicle. After 30 min of treatment, cells were collected for RNA extraction and analysis. RNA was extracted using the Qiagen RNAeasy kit, then sent to the Tufts University Core Facility for library prep and sequencing. Results: Analysis of this data resulted in the identification of a number of possible targets of the Dfi1 pathway, as reported in the manuscript "Bypass of Dfi1 regulation of Candida albicans invasive filamentation by iron limitation".

2022-01-20 | GSE193641 | GEO

Genomic profiling of biliary tract cancer cell lines reveals molecular subtypes and actionable drug targets

Project description:Purpose: Biliary tract cancers (BTCs) carry a very poor prognosis and have no approved targeted therapies. Recent genomic profiling of primary BTCs identified a number of potentially actionable drug targets, however accurate model systems to evaluate these targets are currently lacking. The purpose of this study was to compare the genomic landscape of commonly used BTC cell lines to primary BTCs, and to utilize these models for drug target evaluation. Design: Twenty BTC cell lines were profiled by RNA-seq analysis. Results: Transcriptomic profiling of BTC cell lines identified two subtypes, enriched for epithelial and mesenchymal genes respectively, which were also identified in primary BTC. Conclusions: Cell lines harbor similar genomic alterations to primary BTCs. Integration of cell line and primary cancer data identify novel molecular subsets, and highlight specific molecular vulnerabilities in BTC.

2019-10-12 | GSE138772 | GEO

Actionable diagnosis of neuroleptospirosis by next-generation sequencing.

Project description:A 14-year-old boy with severe combined immunodeficiency presented three times to a medical facility over a period of 4 months with fever and headache that progressed to hydrocephalus and status epilepticus necessitating a medically induced coma. Diagnostic workup including brain biopsy was unrevealing. Unbiased next-generation sequencing of the cerebrospinal fluid identified 475 of 3,063,784 sequence reads (0.016%) corresponding to leptospira infection. Clinical assays for leptospirosis were negative. Targeted antimicrobial agents were administered, and the patient was discharged home 32 days later with a status close to his premorbid condition. Polymerase-chain-reaction (PCR) and serologic testing at the Centers for Disease Control and Prevention (CDC) subsequently confirmed evidence of Leptospira santarosai infection.

| S-EPMC4134948 | biostudies-literature

Next generation sequencing to identify PNISR regulating alternative splicing in CRC

Project description:We performed next generation sequencing between control CRC cells and CRC cells with PNISR knockdown to identify PNISR regulating alternative splicing

2022-08-19 | GSE204973 | GEO

Next generation sequencing to identify GPT1 regulating signaling pathway in CRC

Project description:We performed next generation sequencing between control CRC cells and CRC cells with GPT1 overexpression to identify GPT1 regulating signaling pathway

2024-02-07 | GSE250091 | GEO

Next generation sequencing to identify PNISR regulating alternative splicing in CRC

Project description:Next generation sequencing to identify PNISR regulating alternative splicing in CRC

| PRJNA842909 | ENA